Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management options of breast cancer related osteoporosis.

Literature DB >> 25285137

Management options of breast cancer related osteoporosis.

Angelamaria Becorpi¹, Giovanni Sisti², Flavia Sorbi², Elena Rita Magro Malosso², Secondo Guaschino².

Abstract

Breast cancer therapy after surgery has been improved in recent years. Adjuvant therapies like aromatase inhibitors are being extensively used among breast cancer survivors. This leaded to cancer related and iatrogenic osteoporosis. Management of these patients needs to be focused and differentiated from the standard age related osteoporosis in women. All guidelines consider mandatory to assess fracture risk periodically in all breast cancer survivors. Risk assessment diagnostic FRAX tool is the most used but it's not born specifically for cancer related osteoporosis. The therapeutic management of this kind of osteoporosis has been studied by different societies. Since breast cancer survivors are at risk of osteopenia and osteoporosis, counseling regarding modifiable risk factors is mandatory and advocated. The beginning of the treatment should be tailored in each patient.

Entities: Disease Species

Keywords: bone resorption; breast cancer; drug therapy; osteoporosis; women’s health

Year: 2014 PMID： 25285137 PMCID： PMC4172176

Source DB: PubMed Journal: Clin Cases Miner Bone Metab ISSN： 1724-8914

20 in total

1. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors: Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal: CMAJ Date: 2010-10-12 Impact factor: 8.262

2. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

Authors: H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman
Journal: Ann Oncol Date: 2010-05-05 Impact factor: 32.976

3. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors: Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal: Lancet Oncol Date: 2011-06-05 Impact factor: 41.316

Review 4. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors: Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal: J Natl Cancer Inst Date: 2011-07-09 Impact factor: 13.506

5. Smoking, smoking cessation, and risk of hip fracture in women.

Authors: J Cornuz; D Feskanich; W C Willett; G A Colditz
Journal: Am J Med Date: 1999-03 Impact factor: 4.965

Review 6. Cancer treatment-induced bone loss in breast and prostate cancer.

Authors: Fred Saad; Jonathan D Adachi; Jacques P Brown; Leah A Canning; Karen A Gelmon; Robert G Josse; Kathleen I Pritchard
Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544

7. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Authors: J Compston; A Cooper; C Cooper; R Francis; J A Kanis; D Marsh; E V McCloskey; D M Reid; P Selby; M Wilkins
Journal: Maturitas Date: 2009-01-08 Impact factor: 4.342

8. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Authors: David M Reid; Julie Doughty; Richard Eastell; Steven D Heys; Anthony Howell; Eugene V McCloskey; Trevor Powles; Peter Selby; Robert E Coleman
Journal: Cancer Treat Rev Date: 2008-06-02 Impact factor: 12.111

Management options of breast cancer related osteoporosis.

1. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

2. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

3. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Review 4. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

5. Smoking, smoking cessation, and risk of hip fracture in women.

Review 6. Cancer treatment-induced bone loss in breast and prostate cancer.

7. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

8. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

Review 9. Adverse bone effects during pharmacological breast cancer therapy.

Review 10. Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?

1. An Uncommon Pairing of common Tumors: Case Report of Ductal Carcinoma in situ Within Fibroadenoma.

2. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.